Overview

Genotype and Platelet Reactivity in Patients on Hemodialysis

Status:
Unknown status
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Patients with end stage renal disease (ESRD) on hemodialysis (HD) exhibited higher platelet reactivity to clopidogrel than did those with normal renal function. We recently reported platelet inhibition by ticagrelor was faster and markedly greater than by clopidogrel with onset dosing regimen in patients with ESRD on HD. However, few studies have been conducted genetic influence in high platelet reactivity in patients with ESRD on HD.
Phase:
Phase 3
Details
Lead Sponsor:
Kyunghee University Medical Center
Treatments:
Clopidogrel
Ticagrelor
Ticlopidine